Pharmacokinetics, Safety, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor for Hepatitis C Virus, following Single Ascending Doses in Healthy Subjects

Pharmacokinetics, Pharmacodynamics, and Tolerability of GS-9851, a Nucleotide Analog Polymerase Inhibitor, following Multiple Ascending Doses in Patients with Chronic Hepatitis C Infection

(2012) Eric Lawitz et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A new standard of care for the treatment of chronic HCV infection

(2011) Wolf Peter Hofmann et al.   Nature Reviews Gastroenterology & Hepatology

PSI-7851, a Pronucleotide of  -D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication

(2010) A. M. Lam et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Adverse effects of drugs in the treatment of viral hepatitis

(2010) Francesco Negro   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Emerging therapies for hepatitis C virus

(2010) Aybike Birerdinc et al.   EXPERT OPINION ON EMERGING DRUGS

Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977

(2010) Eisuke Murakami et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Discovery of a β-d-2′-Deoxy-2′-α-fluoro-2′-β-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus

(2010) Michael J. Sofia et al.   JOURNAL OF MEDICINAL CHEMISTRY

HCV drug discovery aimed at viral eradication

(2009) R. F. Schinazi et al.   JOURNAL OF VIRAL HEPATITIS